GlassScriptPhysician profile
Lisa E Hill
NPI 1407231566
$1,473.32
in general payments reported to CMS, 2019-2025
24 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $424 · 2023: $203 · 2024: $146 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $247.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $224.01 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $135.63 | 2021-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $125.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $96.53 | 2021-2023 | |
| Pfizer INC. | $84.27 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.76 | 2022 | |
| Exact Sciences Corporation | $68.46 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $67.36 | 2021-2023 | Veozah |
| Glaxosmithkline, LLC. | $53.28 | 2022-2025 | Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $46.37 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $32.23 | 2022-2023 | Onpattro |
| Dexcom, INC. | $31.42 | 2021-2022 | |
| Globus Medical, INC. | $26.04 | 2025 | Senza |
| Otsuka America Pharmaceutical, INC. | $24.71 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18.07 | 2022 | |
| Genentech USA, INC. | $17.74 | 2021 | |
| Antares Pharma, INC. | $17.54 | 2023 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $17.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.19 | 2021 | |
| Amarin Pharma, INC. | $13.05 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.